HOME ·

01513.HK

LIVZON PHARMA (01513.HK): Leuprorelin 3-Month Formulation Approved
Tags：
LIVZON PHARMA01513.HKNew Drug Application
2026-09-29
LIVZON PHARMA (01513.HK): Proposes Appointment of Zhu Linlin as Non-Executive Director of the Twelfth Board
Tags：
LIVZON PHARMA01513.HK
2026-09-18
LIVZON PHARMA (01513.HK): Zhu Baoguo resigns as Chairman on retirement; President Liu Daping appointed
Tags：
LIVZON PHARMA01513.HKretire
2026-09-11
LIVZON PHARMA (01513.HK): Lecankitug injection approved for marketing; first domestic IL-17A/F dual-target biologic in China
Tags：
LIVZON PHARMA01513.HKClinical Progress
2026-08-27
LIVZON PHARMA(01513.HK): 2026 Q1 Report - Profit Attributable to Shareholders stood at CNY 576.91 million, YoY decrease of 9.39%
Tags：
LIVZON PHARMA01513.HKfinancials
2026-04-24